Eli Lilly Slapped With DoJ Subpoena Over COVID-19 Drug Manufacturing Plant: Reuters

Eli Lilly Slapped With DoJ Subpoena Over COVID-19 Drug Manufacturing Plant: Reuters
  • Eli Lilly and Co LLY has received a subpoena from the U.S. Department of Justice related to its New Jersey plant that makes its COVID-19 treatment, bamlanivimab, reports Reuters.
  • The subpoena requested certain documents relating to its site in Branchburg, New Jersey. It did not specify what documents the subpoena requested.
  • Earlier this month that the company's employees have accused a factory executive of altering documents required by government regulators to downplay serious quality control problems at the Branchburg site.
  • Eli Lilly is also under pressure due to quality control, production, and regulatory issues at its Indianapolis plant, which bottles bamlanivimab, among other drugs.
  • Price Action: LLY shares are down 1.58% at $197.82 during the market session on the last check Thursday.

Posted In: BriefsCovid-19COVID-19 VaccineReutersBiotechNewsHealth CareLegalGeneral